Clinical Trial Update: A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating TQB2450 plus Anlotinib hydrochloride capsule versus Sunitinib in patients with advanced renal cell carcinoma; the study is currently …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Anlotinib hydrochloride capsule (Anlotinib hydrochloride)
• Sunitinib (sunitinib)
• TQB2450

Snippet

Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Conditions: Advanced Renal Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING